Chronic kidney disease: the global challenge

Kidney Disease Outcome Quality Initiative, 2002, Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification, Am J Kidney Dis, 39, S1 Lysaght, 2002, Maintenance dialysis population dynamics: current trends and long-term implications, J Am Soc Nephrol, 13, 37, 10.1681/ASN.V13suppl_1s37 The Renal Association United States Renal Data System, 2003, Annual data report: incidence and prevalence of ESRD (2003), Am J Kidney Dis, 42, S37 King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 De Vecchi, 1999, Healthcare systems and end-stage renal disease: an international review—costs and reimbursement of ESRD therapies, N Engl J Med, 14, 31 McDonald, 2002, ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry, Am J Kidney Dis, 40, 1122, 10.1053/ajkd.2002.36943 Coresh, 2003, Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey, Am J Kidney Dis, 41, 1, 10.1053/ajkd.2003.50007 Clase, 2002, Estimating the prevalence of low glomerular filtration rate requires attention to the creatinine assay calibration, J Am Soc Nephrol, 13, 2812 Hallan, 2004, Validation of the modification of diet in renal disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay, Am J Kidney Dis, 44, 84, 10.1053/j.ajkd.2004.03.027 Coresh, 2002, Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate, Am J Kidney Dis, 39, 920, 10.1053/ajkd.2002.32765 Chen, 2003, Should the K/DOQI definition of chronic kidney disease be changed?, Am J Kidney Dis, 42, 623, 10.1016/S0272-6386(03)00870-9 Chadban, 2003, Prevalence of kidney damage in Australian adults: the AusDiab Kidney Study, J Am Soc Nephrol, 14, S131, 10.1097/01.ASN.0000070152.11927.4A Iseki, 2003, The Okinawa Screening Program, J Am Soc Nephrol, 7, S127, 10.1097/01.ASN.0000070153.91733.09 Hillege, 2001, Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity, J Intern Med, 249, 519, 10.1046/j.1365-2796.2001.00833.x Brown, 2003, Early detection of kidney disease in community settings: the Kidney Early Evaluation Program (KEEP), Am J Kidney Dis, 42, 22, 10.1016/S0272-6386(03)00405-0 Bergman, 1996, Kidney disease in the first-degree relatives of African-Americans with hypertensive end-stage renal disease, Am J Kidney Dis, 27, 341, 10.1016/S0272-6386(96)90356-X Buck, 1999, Diabetes and renal failure in Indo-Asians in the UK: a paradigm for the study of disease susceptibility, Nephrol Dial Transplant, 12, 1555, 10.1093/ndt/12.8.1555 Brenner, 1994, Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury, Am J Kidney Dis, 23, 171, 10.1016/S0272-6386(12)80967-X Klag, 1997, End-stage renal disease in African-Americans and white men: 16-year MRFIT findings, JAMA, 277, 1293, 10.1001/jama.1997.03540400043029 Schaeffner, 2003, Cholesterol and risk of renal dysfunction in apparently healthy men, J Am Soc Nephrol, 14, 2084, 10.1681/ASN.V1482084 Haroun, 2003, Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland, J Am Soc Nephrol, 14, 2934, 10.1097/01.ASN.0000095249.99803.85 Hillege, 2002, Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population, Circulation, 106, 777, 10.1161/01.CIR.0000031732.78052.81 Sarnak, 2003, Kidney disease as a risk factor for development of cardiovascular disease (AHA Scientific Statement), Circulation, 108, 2154, 10.1161/01.CIR.0000095676.90936.80 Go, 2004, Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation, N Engl J Med, 351, 1296, 10.1056/NEJMoa041031 WHO, 2003 Jungers, 1996, Age and gender-related incidence of chronic renal failure in a French urban area: a prospective epidemiologic study, Nephrol Dial Transplant, 11, 1542, 10.1093/ndt/11.8.1542 Hannedouche, 1993, Factors affecting progression in advanced chronic renal failure, Clin Nephrol, 39, 312 Hsu, 2003, Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United States, J Am Soc Nephrol, 14, 2902, 10.1097/01.ASN.0000091586.46532.B4 Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal failure, N Engl J Med, 330, 877, 10.1056/NEJM199403313301301 Jafar, 2003, Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition; a patient level metaanalysis, Ann Intern Med, 139, 244, 10.7326/0003-4819-139-4-200308190-00006 Iseki, 2003, Proteinuria and the risk of developing end stage renal disease, Kidney Int, 63, 1468, 10.1046/j.1523-1755.2003.00868.x Remuzzi, 1998, Pathophysiology of progressive nephropathies, N Engl J Med, 339, 1448, 10.1056/NEJM199811123392007 The Diabetes Control and Complications Trial (DCCT) Research Group, 1995, Effect of intensive therapy on the development and progression of diabetic nephropathy in the DCCT, Kidney Int, 47, 1703, 10.1038/ki.1995.236 Adler, 2003, Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64), Kidney Int, 63, 225, 10.1046/j.1523-1755.2003.00712.x Keane, 1991, The role of altered lipid metabolism in the progression of renal disease: experimental evidence, Am J Kidney Dis, 17, 38 Johnson, 1999, Reappraisal of the pathogenesis and consequences of hyperuricaemia in hypertension, cardiovascular disease, and renal disease, Am J Kidney Dis, 33, 225, 10.1016/S0272-6386(99)70295-7 de Jong, 2002, Obesity and target organ damage: the kidney, Int J Obes Relat Metab Disord, 26, S21, 10.1038/sj.ijo.0802213 Kambham, 2001, Obesity-related glomerulopathy: an emerging epidemic, Kidney Int, 59, 1498, 10.1046/j.1523-1755.2001.0590041498.x Verani, 1992, Obesity-associated focal segmental glomerulosclerosis: pathological features of the lesion and relationship with cardiomegaly and hyperlipidemia, Am J Kidney Dis, 20, 629, 10.1016/S0272-6386(12)70230-5 Bonnet, 2001, Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephropathy, Am J Kidney Dis, 37, 720, 10.1016/S0272-6386(01)80120-7 Orth, 1998, Smoking as a risk factor for end-stage renal failure in men with primary renal disease, Kidney Int, 54, 926, 10.1046/j.1523-1755.1998.00067.x Pinto-Sietsma, 2000, Smoking is related to albuminuria and abnormal renal function in nondiabetic persons, Ann Intern Med, 133, 585, 10.7326/0003-4819-133-8-200010170-00008 Tofovic, 1999, Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats, J Cardiovasc Pharmacol, 33, 360, 10.1097/00005344-199903000-00003 Savoca, 2004, The association of caffeinated beverages with blood pressure in adolescents, Arch Pediatr Adolesc Med, 158, 473, 10.1001/archpedi.158.5.473 Perneger, 1999, Risk of end-stage renal disease associated with alcohol consumption, Am J Epidemiol, 150, 1275, 10.1093/oxfordjournals.aje.a009958 Perneger, 2001, Recreational drug use: a neglected risk factor for end-stage renal disease, Am J Kidney Dis, 38, 49, 10.1053/ajkd.2001.25181 Klag, 1996, Analgesics and chronic renal disease, Curr Opin Nephrol Hypertens, 5, 236, 10.1097/00041552-199605000-00009 Perneger, 1994, Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs, N Engl J Med, 331, 1675, 10.1056/NEJM199412223312502 Morlans, 1990, End-stage renal disease and non-narcotic analgesics: a case-control study, Br J Clin Pharmacol, 30, 717, 10.1111/j.1365-2125.1990.tb03841.x El Nahas, 1988, Glomerulosclerosis: a form of atherosclerosis, Nephrology, 2, 1206 Cybulsky, 2000, Growth factor pathways in proliferative glomerulonephritis, Curr Opin Nephrol Hypertens, 9, 217, 10.1097/00041552-200005000-00003 El Nahas, 2003, Plasticity of kidney cells: role in kidney remodelling and scarring, Kidney Int, 64, 1553, 10.1046/j.1523-1755.2003.00255.x Pavenstadt, 2003, Cell biology of the glomerular podocyte, Physiol Rev, 83, 253, 10.1152/physrev.00020.2002 Zeisberg, 2000, Renal fibrosis: an update, Curr Opin Nephrol Hypertens, 10, 315, 10.1097/00041552-200105000-00004 Schieppati, 2003, Proteinuria and its consequences in renal disease, Acta Paediatr Suppl, 92, 9, 10.1111/j.1651-2227.2003.tb00213.x Iwano, 2004, Mechanism of tubulointerstitial fibrosis, Curr Opin Nephrol Hypertens, 13, 279, 10.1097/00041552-200405000-00003 Fan, 1999, Transforming growth factor-beta regulates tubular epithelial myofibroblast transdifferentiation in vitro, Kidney Int, 56, 1455, 10.1046/j.1523-1755.1999.00656.x Imasawa, 2001, The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells, J Am Soc Nephrol, 12, 1401, 10.1681/ASN.V1271401 Ito, 2001, Bone marrow is a reservoir of repopulating mesangial cells during glomerular remodelling, J Am Soc Nephrol, 12, 2625, 10.1681/ASN.V12122625 Cornacchia, 2001, Glomerulosclerosis is transmitted by bone marrow-derived mesangial cell progenitors, J Clin Invest, 108, 1649, 10.1172/JCI200112916 Imasawa, 2002, Stem cells in renal biology: bone marrow transplantation for the treatment of IgA nephropathy, Exp Nephrol, 10, 51, 10.1159/000049898 Basile, 1999, The transforming growth factor beta system in kidney disease and repair: recent progress and future directions, Curr Opin Nephrol Hypertens, 8, 21, 10.1097/00041552-199901000-00005 Flanders, 2004, Smad3 as a mediator of the fibrotic response, Int J Exp Pathol, 85, 47, 10.1111/j.0959-9673.2004.00377.x Wardle, 2002, Antagonism of nuclear factor kappa B, Nephron, 90, 239, 10.1159/000049056 Guan, 2001, Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease, Kidney Int, 60, 14, 10.1046/j.1523-1755.2001.00766.x Shankland, 1999, Cell cycle regulatory proteins in glomerular disease, Kidney Int, 56, 1208, 10.1046/j.1523-1755.1999.00709.x Lindstrom, 2003, Prevention of diabetes mellitus in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study: results from a randomised clinical trial, J Am Soc Nephrol, 14, S108, 10.1097/01.ASN.0000070157.96264.13 Molich, 2003, The Diabetes Prevention Program and its global implications, J Am Soc Nephrol, 14, S103, 10.1097/01.ASN.0000070140.62190.97 Appel, 2003, Lifestyle modification as a means to prevent and treat high blood pressure, J Am Soc Nephrol, 14, S99, 10.1097/01.ASN.0000070141.69483.5A Moser, 2004, Update on the management of hypertension: recent clinical trials and the JNC 7, J Clin Hypertens, 6, 4, 10.1111/j.1524-6175.2004.03830.x Kidney Disease Outcome Quality Initiative, 2004, Clinical practice guidelines on hypertension and anti-hypertensive agents in chronic kidney disease, Am J Kidney Dis, 43, 1 Klahr, 1994, The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal failure, N Engl J Med, 330, 877, 10.1056/NEJM199403313301301 Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 United Kingdom Prospective Diabetes Study Group, 1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), BMJ, 317, 703, 10.1136/bmj.317.7160.703 Schrier, 2000, Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension, N Engl J Med, 343, 1969, 10.1056/NEJM200012283432614 Bakris, 2000, Preserving renal function in adults with hypertension and diabetes: a consensus approach, Am J Kidney Dis, 36, 646, 10.1053/ajkd.2000.16225 Remuzzi, 2002, Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition, Ann Intern Med, 136, 604, 10.7326/0003-4819-136-8-200204160-00010 Hilgers, 2004, Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?, Pediatr Nephrol, 19, 956, 10.1007/s00467-004-1554-5 Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the African American Study of Kidney Disease trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421 Giatras, 1997, Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials, Ann Intern Med, 127, 337, 10.7326/0003-4819-127-5-199709010-00001 Gaede, 2003, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes, N Engl J Med, 348, 383, 10.1056/NEJMoa021778 Zoja, 2002, How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach, J Am Soc Nephrol, 13, 2898, 10.1097/01.ASN.0000034912.55186.EC Fried, 2001, Effects of lipid reduction on the progression of renal disease: a meta-analysis, Kidney Int, 59, 260, 10.1046/j.1523-1755.2001.00487.x Wald, 2003, A strategy to reduce cardiovascular disease by more than 80%, BMJ, 326, 1419, 10.1136/bmj.326.7404.1419 Imai, 2002, Targeting growth factors to the kidney: myth or reality?, Curr Opin Nephrol Hypertens, 11, 49, 10.1097/00041552-200201000-00008 Kang, 2003, Vascular endothelial growth factor: a new player in the pathogenesis of renal fibrosis, Curr Opin Nephrol Hypertens, 12, 43, 10.1097/00041552-200301000-00008 Ludewig, 2000, PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction, Cell Tissue Res, 299, 97, 10.1007/s004410050009 Sharpe, 2003, Signalling: focus on rho in renal disease, J Am Soc Nephrol, 14, 261, 10.1097/01.ASN.0000048223.05219.E4 Schieppati, 2003, Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries, Kidney Int, 63, 1948, 10.1046/j.1523-1755.2003.00926.x Frame, 1975, A critical review of periodic health screening using specific screening criteria: 3, selected diseases of the genitourinary system, J Fam Pract, 2, 189 McClellan, 2003, Screening for chronic kidney disease: unresolved issues, J Am Soc Nephrol, 14, S81, 10.1097/01.ASN.0000070144.86024.04 Mattix, 2002, Use of the albumin/creatinine ratio to detect microalbuminuria: implications of sex and race, J Am Soc Nephrol, 13, 1034, 10.1681/ASN.V1341034 Hsu, 2002, Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency, Kidney Int, 61, 1567, 10.1046/j.1523-1755.2002.00299.x Golan, 1999, The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors, Ann Intern Med, 131, 660, 10.7326/0003-4819-131-9-199911020-00005 Craig, 2002, Feasibility study of the early detection and treatment of renal disease by mass screening, Intern Med J, 32, 6, 10.1046/j.1445-5994.2002.00155.x Boulware, 2003, Screening for proteinuria in US adults: a cost-effectiveness analysis, JAMA, 290, 3101, 10.1001/jama.290.23.3101 Rockhill, 2000, Individuals risk prediction and population-wide disease prevention, Epidemiol Rev, 22, 176, 10.1093/oxfordjournals.epirev.a018017 Keane, 1999, Proteinuria, albuminuria, risk assessment, detection, elimination (PARADE): a position paper of National Kidney Foundation, Am J Kidney Dis, 33, 1004, 10.1016/S0272-6386(99)70442-7 Feldman, 2003, The Chronic Renal Insufficiency Cohort (CRIC) Study: design and methods, Am Soc Nephrol, 14, S148, 10.1097/01.ASN.0000070149.78399.CE Ruggenenti, 2001, Progression, remission, and regression of chronic renal diseases, Lancet, 357, 1601, 10.1016/S0140-6736(00)04728-0 Hebert, 2001, Renoprotection: one or many therapies, Kidney Int, 59, 1211, 10.1046/j.1523-1755.2001.0590041211.x Pereira, 2000, Optimisation of pre-ESRD care: the key to improved dialysis outcome, Kidney Int, 57, 351, 10.1046/j.1523-1755.2000.00840.x Trivedi, 2002, Slowing the progression of chronic renal failure: economic benefits and patients' perspectives, Am J Kidney Dis, 39, 721, 10.1053/ajkd.2002.31990